SCHEMBL486926

SCHEMBL486926

O=C1C2CCCCC2C(=O)N1O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.41
ALDH1A1 P00352 5/20 0.41
TDP1 Q9NUW8 2/20 0.39
HTT P42858 1/20 0.39
GAA P10253 1/20 0.37
HPGD P15428 1/20 0.37
CYP3A4 P08684 1/20 0.36
TSHR P16473 1/20 0.36
MAPT P10636 1/20 0.36
APEX1 P27695 1/20 0.36
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
ENO1 P06733 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
STAT3 P40763 1/20 0.34
KMT2A Q03164 1/20 0.34
TP53 P04637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL44008 1.00 POLB (0.41) POLBALDH1A1TDP1HTTGAA
SCHEMBL18072219 1.00 POLB (0.41) POLBALDH1A1TDP1HTTGAA
Hydrochloric Acid SCHEMBL5234099 0.97 POLB (0.40) POLBALDH1A1TDP1HTTGAA
Phosphoric Acid SCHEMBL5332637 0.91 ENO1 (0.42) POLBALDH1A1TDP1HTTGAA
Maleic Acid SCHEMBL5334783 0.85 HTT (0.40) POLBALDH1A1HTTGAAHPGD
Fumaric Acid SCHEMBL5334788 0.85 HTT (0.40) POLBALDH1A1HTTGAAHPGD
Cadaverine Tartrate SCHEMBL5328579 0.83 TSHR (0.39) POLBALDH1A1HTTGAAHPGD
SCHEMBL1260990 0.80 POLB (0.37) POLBALDH1A1TDP1CYP3A4TSHR
SCHEMBL31289551 0.80 ALDH1A1 (0.39) POLBALDH1A1TDP1CYP3A4TSHR
SCHEMBL3678309 0.78 ALDH1A1 (0.39) POLBALDH1A1TDP1CYP3A4TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 315 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10000492-B2 Process for producing diazabicyclooctane derivative MEIJI SEIKA PHARMA CO., LTD. (JP) 2018-06-19 US claimed
US-10000491-B2 Process for producing diazabicyclooctane derivative and intermediate thereof MEIJI SEIKA PHARMA CO., LTD. (JP) 2018-06-19 US claimed
US-20170283415-A1 PROCESS FOR PRODUCING DIAZABICYCLOOCTANE DERIVATIVE MEIJI SEIKA PHARMA CO., LTD. (JP) 2017-10-05 US claimed
US-20160264573-A1 PROCESS FOR PRODUCING DIAZABICYCLOOCTANE DERIVATIVE AND INTERMEDIATE THEREOF MEIJI SEIKA PHARMA CO., LTD. (JP) 2016-09-15 US claimed
EP-3050883-A1 PRODUCTION METHOD FOR DIAZABICYCLOOCTANE DERIVATIVE AND INTERMEDIARY BODY THEREOF Meiji Seika Pharma Co., Ltd. (JP) 2016-08-03 EP claimed
EP-2705081-B1 ACTIVATED OXYGEN SCAVENGING COMPOSITIONS FOR PLASTIC CONTAINERS GRAHAM PACKAGING CO (US) 2015-08-19 EP claimed
EP-2705081-A1 ACTIVATED OXYGEN SCAVENGING COMPOSITIONS FOR PLASTIC CONTAINERS Graham Packaging Company, L.P. (US) 2014-03-12 EP claimed
WO-2012154379-A1 ACTIVATED OXYGEN SCAVENGING COMPOSITIONS FOR PLASTIC CONTAINERS GRAHAM PACKAGING COMPANY, L.P. (US) 2012-11-15 WO claimed
US-20120283366-A1 ACTIVATED OXYGEN SCAVENGING COMPOSITIONS FOR PLASTIC CONTAINERS GRAHAM PACKAGING COMPANY, L.P. (US) 2012-11-08 US claimed
EP-1340780-B1 USE OF SELECTED METAL CATALYSTS FOR RING-OPENING POLYMERIZATION OF EPOXIDES SANYO CHEMICAL IND LTD (JP) 2010-07-21 EP claimed
US-6037477-A CONTACTING AN ETHER WITH OXYGEN IN THE PRESENCE OF AN OXIDATION CATALYST TO PRODUCE ESTER OR ANHYDRIDE DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 2000-03-14 US claimed
US-6020522-A Process for producing aromatic hydroxycarboxylic acid derivatives DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 2000-02-01 US claimed
US-5958821-A EPOXIDATION OF AN ALKENE USING A CYCLIC N-HYDROXYIMIDE AND A COCATALYST OF A COMPOUND OF A GROUP 2A OR TRANSITION METAL USING OXYGEN; CATALYST SELECTIVITY; FREE OF PHOSPHO-VANADOMOLYBDIC ACID OR TETRAPHENYLPORPHYRINTOATO MANGANESE DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 1999-09-28 US claimed
EP-0927711-A1 ADAMANTANE DERIVATIVES AND PROCESS FOR PRODUCING THEM Daicel Chemical Industries, Ltd. (JP) 1999-07-07 EP claimed
EP-0897747-A1 NITRATION OR CARBOXYLATION CATALYSTS Daicel Chemical Industries, Ltd. (JP) 1999-02-24 EP claimed
EP-0879812-A1 Process for producing aromatic hydroxycarboxylic acid derivatives Daicel Chemical Industries, Ltd. (JP) 1998-11-25 EP claimed
EP-0878458-A1 Oxidation process of ethers Daicel Chemical Industries, Ltd. (JP) 1998-11-18 EP claimed
EP-0878234-A2 Oxygenation catalyst and process for producing a ketone using the same Daicel Chemical Industries, Ltd. (JP) 1998-11-18 EP claimed
EP-0824962-A1 OXIDATION CATALYST SYSTEM AND PROCESS FOR OXIDATION WITH THE SAME DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 1998-02-25 EP claimed
WO-1995025090-A1 CYCLIC N-ALKENYLOXYIMIDES AND A METHOD FOR THE PREPARATION OF CYCLIC N-ALKENYLOXYIMIDES, THE CORRESPONDING CYCLIC N-ALKOXYIMIDES AND O-ALKOXYAMINES DSM N.V. (NL) 1995-09-21 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10000492-B2 Process for producing diazabicyclooctane derivative OGFOD1, HAAO, CLCN2 POLB 931/4885ALDH1A1 311/4885TDP1 3730/4885
US-20170283415-A1 PROCESS FOR PRODUCING DIAZABICYCLOOCTANE DERIVATIVE OGFOD1, HAAO, CLCN2 POLB 931/4885ALDH1A1 311/4885TDP1 3730/4885
US-20160264573-A1 PROCESS FOR PRODUCING DIAZABICYCLOOCTANE DERIVATIVE AND INTERMEDIATE THEREOF CLCN2, ODC1, KCNN4 POLB 993/4885ALDH1A1 685/4885TDP1 3682/4885
US-10000491-B2 Process for producing diazabicyclooctane derivative and intermediate thereof CLCN2, ODC1, KCNN4 POLB 993/4885ALDH1A1 685/4885TDP1 3682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.